Recombinant Protein for Treatment of Coronary Artery Disease (CAD) and Metabolic Syndrome (MetS)

• Genetic analysis of a kindred displaying marked early onset CAD, type 2 diabetes, hypertension and hypertriglyceridemia identified mutations in a specific gene.
• The protein encoded by this gene is ubiquitously expressed and found in the plasma, the mutations result in loss of its enzymatic function.
• In in vitro studies the wild-type enzyme increased Insulin release in the presence of high glucose (top figure) while in vivo treatment of mice markedly dropped blood glucose levels (lower figure).
• This recombinant protein is a promising candidate for treatment of CAD, MetS and related disorders. 
• IP status: provisional patent application filed.